Skip to main content

Table 1 Baseline characteristics and complications of patients

From: The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial

Characteristic No. of patients (N = 171) Methylprednisolone (N = 83) Control (N = 88) P
Malea 152 (88.9%) 74 (8.4%) 78 (88.6%) 0.914
Age (years) 45.2 ± 12.3 43.7 ± 12.7 46.6 ± 11.8 0.121
Cirrhosisa 139 (81.3%) 67 (80.7%) 72 (81.8%) 0.854
Time from onsetd to admission (days)b 20 (10–30) 16 (10–21) 20 (13–30) 0.083
MELD score 23.3 ± 4.7 22.8 ± 4.0 23.9 ± 5.2 0.132
Lg HBV DNA (IU/ml) 4.8 ± 1.9 4.9 ± 2.0 4.6 ± 1.8 0.383
HBV DNAa
 Positive 150 (87.7%) 70 (84.3%) 80 (90.9%) 0.191
 Negative 21 (12.3%) 13 (15.7%) 8 (9.1%) 0.191
HBeAga
 Positive 90 (52.6%) 43 (51.8%) 47 (53.4%) 0.834
 Negative 81 (47.4%) 40 (48.2%) 41 (46.6%) 0.834
HBsAgb 2582.0 (401.0–6012.0) 2582.0 (422.8–5884.0) 2613.0 (325.4–6197.3) 0.843
No medication with NAs when the disease onseta 127 (74.3%) 58 (69.9%) 69 (78.4%) 0.202
 Never used before 89 (52.0%) 38 (45.8%) 51 (58.0%)  
 Drug withdrawal 38 (22.2%) 20 (24.1%) 18 (20.5%)  
  ADV 6 (3.5%) 2 (2.4%) 4 (4.5%)  
  ETV 16 (9.4%) 12 (14.5%) 4 (4.5%)  
  LAM 10 (5.8%) 4 (4.8%) 6 (6.8%)  
  ETV+ADV 3 (1.8%) 1 (1.2%) 2 (2.3%)  
  LAM+ADV 3 (1.8%) 1 (1.2%) 2 (2.3%)  
Medication with NAs when the disease onseta 44 (25.7%) 25 (30.1%) 19 (21.6%) 0.202
 LAM 7 (4.1%) 4 (4.8%) 3 (3.4%)  
 LAM+TDF 1 (0.6%) 1 (1.2%) 0  
 LAM+ADV 7 (4.1%) 3 (3.6%) 4 (4.5%)  
 ETV 26 (15.2%) 16 (19.3%) 10 (11.4%)  
 ADV 2 (1.2%) 0 2 (2.3%)  
 LdT 1 (0.6%) 1 (1.2%) 0  
NAs therapy after enrollmenta 171 (100%) 83 (100%) 88 (100%) 0.101
 LAM 16 (9.4%) 6 (7.2%) 10 (11.4%)  
 LAM+ADV 7 (4.1%) 5 (6.0%) 2 (2.3%)  
 LAM+TDF 1 (0.6%) 1 (1.2%) 0  
 ETV 142 (83.0%) 69 (83.1%) 73 (83.0%)  
 ETV+ADV 2 (1.2%) 0 2 (2.3%)  
 ADV 1 (0.6%) 0 1 (1.1%)  
 LdT 2 (1.2%) 2 (2.4%) 0  
ALT (U/L)b 307.0 (117.2–573.6) 347.0 (131.7–685.9) 276.3 (106.8–514.1) 0.080
AST (U/L)b 214.0 (156.8–485.0) 291.3 (156.8–515.0) 184.4 (155.5–306.1) 0.054
Bilirubin (μmol/L) 353.9 ± 138.4 335.3 ± 133.8 371.4 ± 141.2 0.089
Albumin (g/L) 31.0 ± 4.1 31.4 ± 3.6 30.7 ± 4.5 0.257
Cholinesterase (IU/L) 3215.8 ± 1165.5 3262.0 ± 1063.3 3172.3 ± 1258.9 0.616
AFP (ng/ml)b 80.0 (33.1–180.0) 86.0 (45.5–240.0) 65.7 (21.7–132.8) 0.150
Cholesterol (mmol/L) 2.3 ± 0.8 2.4 ± 0.9 2.2 ± 0.7 0.059
Blood urea nitrogen (mmol/L) b 4.0 (3.2–6.1) 4.6 (3.1–6.1) 4.3 (3.5–6.3) 0.054
Creatinine (μmol/L)b 66.2 (56.8–81.0) 64.4 (55.4–76.6) 68.0 (58.1–84.5) 0.123
NH3 (μg/dl) 86.5 ± 45.2 89.2 ± 44.9 84.0 ± 45.7 0.449
Triglyceride (mmol/L)b 0.9 (0.6–1.5) 0.8 (0.5–1.7) 0.9 (0.6–1.4) 0.936
White blood cell (× 109/L) 7.3 ± 3.5 7.3 ± 3.4 7.3 ± 3.6 0.960
Lymphocyte percentage 20.7 ± 8.5 20.1 ± 8.1 21.3 ± 8.9 0.372
Monocyte percentage 9.5 ± 3.6 9.0 ± 3.5 9.8 ± 3.7 0.147
Lymphocyte/monocyte ratiob 2.2 (1.5–3.0) 2.2 (1.5–3.0) 2.1 (1.5–2.9) 0.502
Neutrophil percentage 68.6 ± 10.6 69.1 ± 9.6 68.1 ± .11.4 0.547
Procalcitonin (μg/L)b 0.6 (0.4–0.9) 0.6 (0.5–1.0) 0.6 (0.3–0.8) 0.197
PT (s)b 22.9 (20.2–27.9) 22.9 (19.2–22.8) 22.9 (20.7–27.6) 0.877
PTA (%) 35.9 ± 9.2 36.0 ± .10.3 35.8 ± 8.1 0.865
INRa 2.9 (1.7–2.3) 2.1 (1.6–2.6) 2.0 (1.7–2.2) 0.580
Red blood cell (× 1012/L) 3.9 ± 0.8 4.0 ± 0.8 3.8 ± 0.9 0.070
Hemoglobin (g/L) 124.2 ± 21.1 127.6 ± 18.9 121.5 ± 22.3 0.056
Platelet (×109/L) 105.2 ± 51.6 113.0 ± 45.3 97.9 ± 56.1 0.055
Ascitesa 103 (60.2%) 45 (54.2%) 58 (65.9%) 0.118
Infectionsa 92 (53.8%) 47 (56.6%) 45 (51.1%) 0.472
Electrolyte disturbancea 17 (9.9%) 5 (6.0%) 12 (13.6%) 0.096
Encephalopathya 21 (12.3%) 12 (14.5%) 9 (10.2%) 0.400
Hypoalbuminemiaa 35 (20.5%) 16 (19.3%) 19 (21.6%) 0.708
Hepatorenal syndromea 5 (2.9%) 1 (1.2%) 4 (4.5%) 0.369
Pleural effusiona 7 (4.1%) 3 (3.6%) 4 (4.5%) 1.000
Hyperthyroidisma 1 (0.6%) 1 (1.2%) 0 0.485
Peptic ulcera 2 (1.2%) 1 (1.2%) 1 (1.1%) 1.000
Artificial liver support after enrollmentc 87.98 84.13 0.582
Artificial centesis after enrollmentc 79.55 92.08 0.090
The time of antibiotic use after enrollmentc 91.72 80.60 0.141
  1. aData expressed with number of cases
  2. bData expressed as median (range)
  3. cDate expressed with mean rank
  4. dOnset: appearance of nausea, poor appetite, jaundice, or gastrointestinal hemorrhage